Floatz logo

Atg-010

NK/T-cell Lymphoma

Antengene CorporationPhase 1/2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the NK/T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Mesna
Antengene Corporation
Phase 4BB
Rivoceranib
Peking University
Phase 2CCC
Eloxatin
Antengene Corporation
Phase 1/2CCC
Anti-Cd30-Car-Transduced T Cells
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1CC
Ebv Tcr-T
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1C

Same molecule, other indications

Atg-010 is also rated in:

relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
49 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
45 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →